Failure to Warn Under Louisiana Law
Louisiana governs product liability claims through the Louisiana Products Liability Act (LPLA), found at La. R.S. 9:2800.51 through 9:2800.59. The LPLA is the exclusive remedy for injuries caused by defective products in Louisiana. One of the four recognized theories of liability under the LPLA is inadequate warning.
La. R.S. 9:2800.57 specifically addresses failure to warn claims. Under this statute, a product is unreasonably dangerous when it does not have an adequate warning about a characteristic that may cause damage and the manufacturer knew or should have known about. The statute places the duty to warn squarely on the manufacturer, not on distributors or retailers in the supply chain.
A failure to warn claim does not require proof that the product itself was poorly designed or manufactured. The product may function exactly as intended. The legal issue is whether the manufacturer gave adequate notice of risks associated with the product's use. This distinction matters because a product can be safe when used with proper knowledge but dangerous when used without it.
What Constitutes an Adequate Warning
La. R.S. 9:2800.57 identifies three factors courts evaluate when determining whether a warning was adequate. First, the warning must address the characteristics of the product that could cause damage. Second, it must convey the degree of danger involved. Third, the feasibility of providing an effective warning is considered.
An adequate warning must be specific enough to inform a reasonable user of the actual risk. General statements such as "use with caution" or "may be harmful" do not satisfy the statute. The warning must identify the particular hazard, explain the potential consequences, and provide instructions to avoid the danger.
The warning must also reach the end user in a form they can understand. Placement matters. A warning buried on page 47 of a technical manual may not be adequate if the hazard could cause serious injury during ordinary use. Louisiana courts consider whether the warning was prominent, clearly written, and accessible to the person using the product.
The standard applies to "reasonably anticipated use" of the product. This includes not only the product's intended purpose but also uses the manufacturer should foresee. A manufacturer of industrial solvents, for example, must warn about risks from skin contact even if the product is designed for surface cleaning, because skin exposure during application is foreseeable.
Common Failure to Warn Claims
Failure to warn claims arise across a wide range of products. Pharmaceutical cases are among the most common. Drug manufacturers must disclose known side effects, drug interactions, and contraindications. When a manufacturer knows about a serious adverse reaction and fails to include it in the labeling, injured patients may have a claim under the LPLA.
Chemical products used in industrial and household settings also generate failure to warn claims. Workers exposed to toxic substances without adequate safety information may suffer respiratory damage, chemical burns, or long term organ damage. The manufacturer's duty extends to providing Safety Data Sheets and product labels that accurately describe exposure risks and required protective equipment.
Industrial equipment and machinery present another category. Manufacturers must warn about pinch points, electrical hazards, moving parts, and other dangers that could cause injury during operation or maintenance. Louisiana courts have found manufacturers liable when workers were injured by equipment that lacked clear warnings about specific operational hazards.
Consumer products including power tools, children's items, appliances, and recreational equipment also give rise to these claims. A product sold to the general public requires warnings written in plain language, not technical jargon. The manufacturer must account for the fact that ordinary consumers may lack specialized knowledge about the product's risks.
The Learned Intermediary Doctrine
Louisiana recognizes the learned intermediary doctrine for prescription medications and medical devices. Under this doctrine, the manufacturer's duty to warn runs to the prescribing physician rather than directly to the patient. The reasoning is that a physician acts as an intermediary who can evaluate risks and benefits for each individual patient.
When the learned intermediary doctrine applies, the manufacturer satisfies its warning obligation by providing adequate information to the prescribing doctor. The doctor then assumes responsibility for communicating relevant risks to the patient. If the manufacturer gave the physician complete and accurate risk information, the manufacturer may not be liable even if the patient was unaware of the risk.
This doctrine has limits. It does not apply to over the counter medications or products that do not require a prescription. It also does not protect a manufacturer that provided misleading or incomplete information to the physician. If the manufacturer downplayed a known risk in its communications to doctors, the doctrine will not serve as a defense.
Proving a Failure to Warn Claim
To succeed on a failure to warn claim under the LPLA, the injured person must prove several elements. The product must have lacked an adequate warning about a dangerous characteristic. The manufacturer must have known or should have known about the danger at the time the product left its control. The lack of adequate warning must have been a cause of the claimant's injury.
Causation requires showing that an adequate warning would have changed the outcome. Louisiana courts apply a "heeding presumption" in some failure to warn cases. This presumption holds that if an adequate warning had been provided, the user would have read it and followed it. The manufacturer can rebut this presumption with evidence that the user would have ignored the warning regardless.
The manufacturer also has a post sale duty to warn in certain circumstances. If a manufacturer learns about a product hazard after the product has been sold, it may be required to take reasonable steps to notify users. This obligation arises when the manufacturer becomes aware of a danger that was not known at the time of sale and the risk of harm is serious.
Expert testimony often plays a significant role in failure to warn litigation. Engineers, toxicologists, medical professionals, and human factors experts may testify about the adequacy of warnings, the foreseeability of the risk, and whether a proper warning would have prevented the injury.
Filing Deadlines and Comparative Fault
Louisiana law imposes strict filing deadlines for product liability claims. For injuries arising from incidents on or after July 1, 2024, the prescriptive period is two years from the date of injury. Claims not filed within this period are generally barred. The LPLA also includes a peremptive period that can limit claims based on the age of the product.
Louisiana applies comparative fault principles to product liability cases. Under La. C.C. art. 2323, a court or jury assigns a percentage of fault to each party, including the injured person. If the injured person misused the product in a way that was not reasonably foreseeable, or ignored an existing warning, their recovery may be reduced by their assigned percentage of fault.
For claims arising from incidents on or after January 1, 2026, Louisiana's 51% comparative fault bar applies. If the injured person is found to be 51% or more at fault, they recover nothing. This makes the adequacy of the warning even more significant, because manufacturers may argue that the user's own conduct was the primary cause of the injury.
Product liability cases involving inadequate warnings require detailed investigation into the product's history, the manufacturer's knowledge of risks, and the content of existing labels and instructions. Consulting an attorney familiar with the LPLA and Caddo Parish court procedures is an important step toward understanding whether a viable claim exists.